Speeding up access to clinical trials
The approach relies on a unique clinical and pharmaceutical development expertise in the field of rare inborn errors of metabolism and repurposing of existing molecules of the pharmacopeia.
This approach speeds up the process of drug development.
Three molecules and a research platform are currently in development
Three drugs are currently in development:
- MD1003 in primary and secondary progressive multiple sclerosis
- MD1103 in autism spectrum disorders
- MD1105 in Alzheimer’s disease
A research platform aiming at discovering new therapeutic targets through cerebrospinal fluid metabolomic analysis is in development, in partnership with Assistance Publique Hopitaux de Paris (APHP) and Commissariat à l’Energie Atomique (CEA).
Market Launch in 2017
MD1003 is currently investigated in 2 pivotal phase III studies in France, involving 250 patients. The first patient was included in October 2013.
The company tightly works with regulatory agencies.
Market launch in multiple sclerosis is expected by 2017.